Antiandrogens as Monotherapy for Prostate Cancer

@article{Schrder1998AntiandrogensAM,
  title={Antiandrogens as Monotherapy for Prostate Cancer},
  author={Fritz H. Schr{\"o}der},
  journal={European Urology},
  year={1998},
  volume={34},
  pages={12 - 17}
}
  • F. Schröder
  • Published 1 October 1998
  • Medicine
  • European Urology
Castration or antiandrogen monotherapies remain options for prostate cancer treatment as only marginal benefits have been demonstrated with combined androgen blockade, although it may be that certain subgroups of patient may benefit. Of the nonsteroidal antiandrogens, bicalutamide 150 mg was as effective as castration in M0 patients with significant improvement in sexual interest and physical capacity, but the trial has yet to reach maturity. In M1 patients, bicalutamide 150 mg was not as… Expand
Quality of Life Issues Relating to Endocrine Treatment Options
TLDR
Data from two large studies of bicalutamide monotherapy show that this non-steroidal antiandrogen is associated with significant health-related quality of life advantages in the treatment of patients with locally advanced (M0) disease compared with castration, suggesting that this treatment may benefit patients with early disease. Expand
Orchidectomy following Failure of Antiandrogen Monotherapy in Patients with Metastatic Prostate Cancer
TLDR
Patients with metastatic prostate cancer who are initially treated by oral antiandrogens and then have progressive disease may be offered surgical castration as a second–line treatment following relapse on antiandrogen monotherapy are reviewed. Expand
Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies
TLDR
This review assesses the present status of hormonal therapy in metastatic prostate cancer and specifically deals with those aspects of androgen ablation therapy that are still a subject of debate. Expand
Immediate vs. delayed androgen deprivation for prostate cancer
TLDR
In the absence of clear guidelines, data from past literature and ongoing modern studies were compiled in the present review in an attempt to generate practical considerations. Expand
Rising Prostate-Specific Antigen after Primary Treatment of Prostate Cancer: Sequential Hormone Manipulation
TLDR
The majority of patients with isolated prostate-specific antigen (PSA) relapse are not candidates for salvage treatment with curative intent and biochemical-only progression after definitive treatment inCurative intent is different from objective or even symptomatic relapse and allows for sequential hormonal therapy with a variety of compounds. Expand
Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer.
TLDR
Although having some effect on disease recurrence, adjuvant flutamide treatment does not improve median-term overall survival after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Expand
Trends in Hormonal Management of Prostate Cancer:: A Population-Based Study in Ontario
TLDR
A population-based description of current practice in the use of hormonal management of prostate cancer in Ontario, Canada, from July 1992 through December 1998 is provided to provide current information on the advantages and disadvantages of different therapeutic options, and quality of life. Expand
Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study.
TLDR
The hypothesis that any antiandrogen, irrespective of the mode of action, would alter the natural history of BPH-associated hematuria is supported, and the results indicate that the speed of action of FIN may not be as rapid as previously described. Expand
Hepatotoxicity Induced by Antiandrogens: A Review of the Literature
TLDR
Although there are differences in the clinical features of hepatotoxicity induced by steroidal and nonsteroidal antiandrogens, these do not predict which patients will develop hepatot toxicity during treatment or evolution. Expand
Treatment options after failure of local curative treatments in prostate cancer: a controversial issue
TLDR
The differentiation of local and distant recurrence, the ef®cacy of the different modalities for treating recurrence and the optimal timing for initiating treatment after biochemical failure are discussed. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 29 REFERENCES
Are Non-Steroidal Anti-Androgens Appropriate as Monotherapy in Advanced Prostate Cancer?
TLDR
Preliminary findings indicate that flutamide may be as effective as orchidectomy in terms of prolonging progression-free survival in selected patients and bicalutamide is well tolerated as monotherapy and appears to be aseffective as castration in patients with locally advanced non-metastatic disease. Expand
A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.
TLDR
A comparison of pharmacologic effects showed that only the incidence of hot flushes was lower in the bicalutamide group, whereas breast tenderness and gynecomastia were more common, which translated into better quality of life during the first several months with regard to sexual relations and sexual functioning. Expand
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
TLDR
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade. Expand
Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
  • A. Chang, B. Yeap, +8 authors D. Trump
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
TLDR
As the primary hormonal therapy for stage D2 prostate cancer, DES caused more serious cardiovascular or thromboembolic complications than flutamide, andFlutamide was not as active an initial agent as DES, however, the effectiveness of flutamia in conjunction with other agents compared with DES remains undetermined. Expand
Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients
TLDR
The currently available evidence from randomised trials does not show that MAB results in longer survival than conventional castration, and Logrank time-to-death analyses found no significant heterogeneity between trials (or between the effects of different types of MAB). Expand
Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate.
TLDR
In the present limited material, there was an initial favorable response to flutamide without signs of CV complications and with maintained libido in most cases, but due to significantly increased risk for relapse compared with estramustine,Flutamide cannot be recommended as single therapy except in cases where estrogens are contraindicated or when interference with libido and potency is unacceptable. Expand
Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
TLDR
There was evidence of benefit from treatment with Casodex in maintaining both sexual interest and functioning, and there were no consistent differences between treatments for other aspects of quality of life. Expand
Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
TLDR
There was evidence of benefit from treatment with Casodex in maintaining both sexual interest and functioning, and there were no consistent differences between treatments for other aspects of quality of life. Expand
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
TLDR
Bicalutamide 150-mg monotherapy provides a similar survival outcome to castration in previously untreated patients with nonmetastatic advanced prostate cancer and confers statistically significant benefits over castration with respect to sexual interest and physical capacity. Expand
Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
Patients with previously untreated category T3 to T4 Mo or Ml prostatic cancer were allocated randomly to receive 250 mg. cyproterone acetate per day, a loading dose of 500 mg. medroxyprogesteroneExpand
...
1
2
3
...